Browse > Article
http://dx.doi.org/10.15324/kjcls.2019.51.4.406

Correlation between Uterine Cervical Lesion and HPV in Busan Region  

Son, Chang Min (Department of Pathology, Inje University Haeundae Paik Hospital)
Park, Chung Mu (Department of Biomedical Health Science, Graduate School of Dong-Eui University)
Publication Information
Korean Journal of Clinical Laboratory Science / v.51, no.4, 2019 , pp. 406-413 More about this Journal
Abstract
This study was undertaken to investigate the distribution of human papillomavirus (HPV) subtypes and cervical lesions in Busan. Furthermore, the cytological and histological findings of cervical lesions were compared to determine the usefulness of the currently released vaccines. HPV subtypes of 2,130 patients who visited Haeundae Paik Hospital between January 2013 and March 2016 were analyzed by the HPV 9G DNA chip. Liquid-based cytological examination was performed, and subtypes were classified according to the 2001 guidelines of The Bethesda System. Biopsy or hysterectomy specimens were subjected to hematoxylin and eosin staining for histological examinations. Of the total 2,130 cases, 1,254 (58.9%) were positive for HPV, and 876 (41.1%) were negative. Of these, 152 (7.1%), 97 (4.6%) and 80 (3.8%) were identified as HPV 16, 68 and 56, respectively. Of the 329 cases encompassing the above three HPV subtypes, histopathological analysis diagnosed 155 (47.1%) cases with CIN2 or higher grade. Notably, the occurrences of HPV subtypes 16, 68, 56, 58 and 51 were most frequently diagnosed in Busan. Further analysis revealed that administration of GardasilⓇ 9, the currently available vaccine in the market, exerts no protection against subtypes 68, 59 and 51. This study aims to provide an important reference for future HPV vaccination programs in Busan.
Keywords
Bethesda system; Hematoxylin-Eosin; Human papillomavirus; Papanicolaou;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. New technologies for cervical Cancer screening (NTCC) working group: efficacy of human papillomavirus testing for the detection of invasive cervical cancer and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257.   DOI
2 Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208:184E1-184E11.   DOI
3 Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12:880-890.   DOI
4 Park SM, Lee SK, Kim YS. Inhibition of cervical cancer cell growth by gene silencing of HPV16 E6 Induced by short-interfering RNA. Korean J Clin Lab Sci. 2011;43:89-97.
5 Lee JB, Park CE. Investigation of detected by recent various human papillomavirus from general hospital in Seoul area. Korean J Clin Lab Sci. 2016;48:247-254.   DOI
6 Bauer H, Hildesheim A, Schiffman NH. Determinants of genital human papillomavirus infection in low-risk women Portland, Oregon. Sex Transm Dis. 1993;20:274-278.   DOI
7 Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):12-23.
8 Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, Monsonego J, et al. EUROGIN 2010 roadmap on cervical cancer prevention. Int J Cancer 2011;128:2765-2774.   DOI
9 Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guideline. Obstet Gynecol. 2015;125:330-337.   DOI
10 Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-935.   DOI
11 Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M. The Bethesda System 2001: terminology for reporting the results of cervical. JAMA. 2002;287:2114- 2119.   DOI
12 Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, Cheng AF. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol. 1999;59:232-238.   DOI
13 Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res. 2002;89:183-190.   DOI
14 Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancer and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol. 2010;11:249-257.   DOI
15 Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines 2015;14:1047-1049.   DOI
16 Hang D, Jia M, Ma H, Zhou J, Feng X, Lyu Z, et al. Independent prognostic role of human papillomavirus genotype in cervical cancer. BMC Infect Dis. 2017;17:391.   DOI
17 de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.   DOI
18 Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. et al. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-355.   DOI
19 Committee on Practice Bulletins-Gynecology: ACOG practice bulletin number 131: Screening for cervical cancer. Obstet Gynecol. 2012;120:1222-1238.   DOI
20 So KA, Hong JH, Lee JK. Human papillomavirus prevalence and type distribution among 968 women in South Korea. J Cancer Prev. 2016;21:104-109.   DOI
21 Kim S, Lee IS, Lee D. Human papillomavirus prevalence and genotype distribution in normal and ASCUS specimens: comparison of a reverse blot hybridization assay with a DNA chip test. Biomed Sci Lett. 2015;21:32-39.   DOI
22 Kim SH, Lee DS, Kim Y, Kim GH, Park SJ, Choi YI, et al. Clinical evaluation of human papillomavirus DNA genotyping assay to Diagnose Women Cervical Cancer. Biomed Sci Lett. 2012;18:123-130.
23 Cho NH, An HJ, Jeong JK, Kang S, Kim JW, Kim YT, et al. Genotyping of 22 human papillomavirus types by DNA chip in korean women: comparison with cytologic diagnosis. Am J Obstet Gynecol. 2003;188:56-62.   DOI
24 Hwang TS, Jeong JK, Park M, Han HS, Choi HK, Park TS. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray. Gynecol Oncol. 2003;90:51-56.   DOI
25 Cho H, Lee DW, Choe YJ, Choe SA, Park NY. Publication of the Korea-WHO cooperation history - 70 years of working together for heath: world health organization and the Republic of Korea. J Korean Med Sci. 2017;32:383-385.   DOI
26 Meng YH1, Li S, Hu T, Ma D, Lu YP, Wang H. Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma. Chin J Cancer. 2010;29:15-19.   DOI
27 Ferlay J, Soerjomataram I, Dikshit R, Ervik M, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359-386.
28 Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133-1145.   DOI
29 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-1953.   DOI